Description
This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and therapeutic use of a lung-directed immunomodulator, to prevent serious COVID-19 infection.
Amendment chain · 7 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $109,764 at start, $2,780,109 after amendment #7 (+$2,670,345).
- #02020-12-01$109,764
- #22021-03-19$229,764+$120,000
- #32021-06-11$2,200,959+$1,971,195
- #42021-11-01$2,200,959
- #52022-03-15$2,200,959
- #62022-06-03$2,940,481+$739,522
- #72022-08-30$2,780,109-$160,372
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-12-01(start date) | $109,764 | — | This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and thera… |
| #2 amendment | 2021-03-19 | $229,764 | +$120,000 | This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and thera… |
| #3 amendment | 2021-06-11 | $2,200,959 | +$1,971,195 | This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and thera… |
| #4 amendment | 2021-11-01 | $2,200,959 | +$0 | This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and thera… |
| #5 amendment | 2022-03-15 | $2,200,959 | +$0 | This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and thera… |
| #6 amendment | 2022-06-03 | $2,940,481 | +$739,522 | This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and thera… |
| #7 amendment | 2022-08-30 | $2,780,109 | −$160,372 | This project will provide proof-of-concept evidence for the safety and efficacy for the prophylactic and thera… |
Related records · 11
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 842333817)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2024-2025-Q1-1018795 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $11,642 | FY2025 |
| 172-2022-2023-Q2-995430 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $5,176,172 | FY2023 |
| 172-2020-2021-Q4-966282 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $37,933 | FY2021 |
| 172-2020-2021-Q2-955668 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $38,170 | FY2021 |
| 172-2020-2021-Q3-960196 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $85,232 | FY2021 |
| 172-2020-2021-Q1-951033 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $71,148 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q3-961167 · retrieved 2026-11-12.